This company listing is no longer active
ProMIS Neurosciences Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
ProMIS Neurosciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been declining at an average rate of 8.3% per year.
Wichtige Informationen
-21.7%
Wachstumsrate der Gewinne
-4.0%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 51.1% |
Wachstumsrate der Einnahmen | -8.3% |
Eigenkapitalrendite | n/a |
Netto-Marge | n/a |
Letzte Ertragsaktualisierung | 31 Mar 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie ProMIS Neurosciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
31 Mar 23 | 0 | -21 | 8 | 0 |
31 Dec 22 | 0 | -18 | 8 | 0 |
30 Sep 22 | 0 | -12 | 6 | 0 |
30 Jun 22 | 0 | -8 | 5 | 0 |
31 Mar 22 | 0 | -6 | 5 | 0 |
31 Dec 21 | 0 | -10 | 4 | 0 |
30 Sep 21 | 0 | -8 | 2 | 0 |
30 Jun 21 | 0 | -8 | 1 | 0 |
31 Mar 21 | 0 | -9 | 2 | 0 |
31 Dec 20 | 0 | -4 | 2 | 0 |
30 Sep 20 | 0 | -5 | 2 | 0 |
30 Jun 20 | 0 | -5 | 2 | 0 |
31 Mar 20 | 0 | -5 | 2 | 0 |
31 Dec 19 | 0 | -6 | 2 | 0 |
30 Sep 19 | 0 | -7 | 2 | 0 |
30 Jun 19 | 0 | -8 | 2 | 0 |
31 Mar 19 | 0 | -8 | 2 | 0 |
31 Dec 18 | 0 | -7 | 2 | 0 |
30 Sep 18 | 0 | -6 | 2 | 0 |
30 Jun 18 | 0 | -5 | 2 | 0 |
31 Mar 18 | 0 | -5 | 2 | 0 |
31 Dec 17 | 0 | -5 | 2 | 0 |
30 Sep 17 | 0 | -5 | 2 | 0 |
30 Jun 17 | 0 | -4 | 2 | 0 |
31 Mar 17 | 0 | -3 | 1 | 0 |
31 Dec 16 | 0 | -3 | 1 | 0 |
30 Sep 16 | 0 | -2 | 1 | 0 |
30 Jun 16 | 0 | -2 | 1 | 0 |
31 Mar 16 | 0 | -2 | 1 | 0 |
31 Dec 15 | 0 | -2 | 1 | 0 |
30 Sep 15 | 0 | -1 | 1 | 0 |
30 Jun 15 | 0 | -2 | 1 | 0 |
31 Mar 15 | 0 | -2 | 1 | 0 |
31 Dec 14 | 0 | -2 | 1 | 0 |
30 Sep 14 | 0 | -3 | 1 | 0 |
30 Jun 14 | 0 | -2 | 1 | 0 |
31 Mar 14 | 0 | -2 | 1 | 0 |
31 Dec 13 | 0 | -2 | 1 | -1 |
30 Sep 13 | 0 | -2 | 1 | -1 |
30 Jun 13 | 0 | -2 | 1 | 0 |
31 Mar 13 | 0 | -2 | 1 | 0 |
31 Dec 12 | 0 | -2 | 1 | 2 |
30 Sep 12 | 0 | -3 | 1 | 2 |
Qualität der Erträge: PMN is currently unprofitable.
Wachsende Gewinnspanne: PMN is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: PMN is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
Beschleunigtes Wachstum: Unable to compare PMN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: PMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: PMN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.